Skip to main content

December 2016

 

 

academics

 

Clinical research courses

McKesson Corporation, a leading international healthcare services and information technology company, announced that it has completed the previously announced acquisition of Rexall Health for 2.9 billion CAD (2.1 billion USD, or approximately 1.7 billion USD, net of certain estimated purchase price adjustments, proceeds from store divestitures, and tax benefits). This follows the agreement reached with the Competition Bureau of Canada for the acquisition of Rexall Health and approval received under the Investment Canada Act

As part of the transaction, McKesson has acquired approximately 470 retail pharmacies, and has agreed to divest stores in 26 local markets that the Competition Bureau of Canada identified during its review of the transaction.

McKesson also announced that Domenic Pilla has been appointed CEO of McKesson Canada, effective January 3, 2017. Pilla will report to Paul C. Julian, executive vice president and group president, McKesson Corporation, and assume overall leadership responsibility for McKesson’s distribution and retail businesses in Canada, including Rexall Health. Jürgen Schreiber, currently CEO of Rexall Health, will leave to pursue other opportunities.

“Today’s announcement marks a milestone for McKesson and Rexall Health. With complementary assets, industry expertise, and shared values, we will now serve our customers with enhanced retail pharmacy capabilities and a broader reach across Canada,” said John H. Hammergren, chairman and chief executive officer, McKesson Corporation. “Patients across Canada will benefit from best-in-class pharmacy care through innovative care solutions and an expanded retail footprint. We are thankful to Daryl Katz, founder and chairman of Katz Group, one of Canada’s largest privately-owned enterprises, for having built such a strong pharmacy asset in the Canadian market.”


With Rexall Health, McKesson will be able to serve a broad range of pharmaceutical care and ensure choice to consumers at a time when Canadians are increasingly turning to pharmacies for their healthcare advice and services.

“Together, McKesson and Rexall can leverage shared expertise to grow and deliver better care and value to Canadians,” said Julian. “McKesson has a strong track record of delivering leading service levels to customers and patients.”


“Domenic Pilla is uniquely qualified to lead our expanded portfolio in Canada based on his previous experience as president of Shoppers Drug Mart and McKesson Canada,” Julian continued. “He brings deep knowledge of both the wholesale and retail sides of the business, and a proven track record of delivering results. We thank Jürgen Schreiber for his outstanding leadership in bringing this acquisition to fruition and wish him the greatest success.”

Rexall Health will continue to have a dedicated management team in Canada under Pilla, while retaining the existing brand Canadians have come to know and trust. Pilla is expected to appoint a new president of Rexall Health in the future to provide day-to-day leadership for Rexall. His other direct report will be Paula Keays, president of McKesson Canada.

McKesson now expects Rexall Health to be flat to adjusted earnings per diluted share for Fiscal 2017 as earnings attributable to Rexall Health will be offset by an anticipated charge related to a fair value adjustment of acquired inventory.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email

Cempra, Inc. announced that the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) relating to the company's new drug applications (NDAs) for oral and intravenous solithromycin for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

Achillion Pharmaceuticals, Inc. announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection (HCV) without cirrhosis.

Recruitment for B.Pharm, M.Pharm work in Central Drugs Testing Laboratory - 10 posts | Ministry of Health & Family Welfare

Central Drugs Testing Laboratory, Hyderabad is statutory laboratory working under administrative control of Drugs Controller General (India), CDSCO, DGHS, Min. of Health & Family Welfare, New Delhi, Application form eligible candidates are invited in the prescribed format for the Recruitment of following posts at Central Drugs Testing Laboratory, Hyderabad. The appointments of the following posts are purely on contractual basis for one year w.e.f 01-01-2017 to 31-12-2017. The contractual period may be reduced or extended at the sole discretion of the management (CDSCO, HQ). During the contract period the services can be terminated without any notice or without assigning any reasons whatsoever.

Post: Bench Chemist

Vacancies for Pharmacist in Office of the CDMO | Government Job

Applications are invited from eligible candidates for the post of Pharmacist in the prescribed format given below for selection and engagement on contractual basis under the administrative control of CDMO The application for the above posts should reach in the office of the CDMO Boudh, Pin - 762014 through Speed Post & Regd. Post only on or before 09 01 2017 by 5 PM The applications received after the due date shall not be considered under any circumstances

Post : Pharmacist

Vacancy for Junior Research fellow at NIPER | walk in

National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as an 'Institute of National Importance'. It is an autonomous body set up under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The Institute is conceived to provide leadership in pharmaceutical sciences and related areas not only within the country, but also to the countries in South East Asia, South Asia and Africa. NIPER is a member of Association of Indian Universities and Association of Commonwealth Universities.

Applications are invited from eligible candidate for filling up the following temporary position for the sponsored project from the DST - Science and Engineering Research Board (SERB) to be undertaken in the Department of Pharmacology and Toxicology of this Institute. The position is temporary and the offer will be initially for a period of ONE Year that can be extended further based on the performance and will be co terminus with the project. If the candidate also fulfils the institute criteria, admission in Ph.D through NIPER entrance may be considered. The requisite qualification & experience etc. are given below.

Job Opportunities in Central Drugs Testing Laboraory as Bench Chemist - 05 posts | Government Jobs

Central Drugs Testing Laboraory.Mumbai is statutory laboratory working under administrative control of Drugs Controller General ( India).CDSCO,DGHS,Min.of Health & Family Wellare.New Delhi. Application from eligible candidates arc invited in the prescribed format for the Recruitment of following posts at Central Drugs Testing Laboratory .Mumbai .The appointments of the following posts are purely on contractual basis for one year w.e.f. 01.1.2017 to 31.12.2017. The contractual period may be reduced or extended at the sole discretion of the management (CDSCO-ITQ).During the contract period the services can be terminated without any notice or without assigning any reasons whatsoever.

Post: Bench Chemist

The Union Cabinet chaired by the Prime Minister Shri Narendra Modi has approved the sale of surplus land of Hindustan Antibiotics Limited (HAL), Indian Drugs & Pharmaceuticals Limited (IDPL), Rajasthan Drugs & Pharmaceuticals Limited (RDPL) and Bengal Chemicals & Pharmaceuticals Limited (BCPL), as would be required, to meet their outstanding liabilities. In this way, the national assets would be utilized in the best national interest.

Working opportunity for Research Assistant - Stability - Analytical R&D in Perrigo | M.Sc, B.Pharm/M.Pharm

Perrigo, headquartered in Ireland is One of the World’s leading Pharmaceuticals Manufacturers, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. Nearly 13,000 Perrigo employees around the world commit themselves each day to the important mission of making Quality Affordable Healthcare Products. Over 3,000 unique formulations with over  18,000 SKUs, 50 Billion Oral solid and liquid/cream doses every year.

Post: Research Assistant - Stability - Analytical R&D